CP-GEP identifies high-risk T1a melanoma patients beyond established adverse features

J Am Acad Dermatol. 2026 Feb;94(2):661-663. doi: 10.1016/j.jaad.2025.10.036. Epub 2025 Oct 13.
No abstract available

Keywords: CP-GEP; Merlin Assay; melanoma; metastasis; risk prediction; sentinel lymph node biopsy.